Quick Liquidity Indicator: Plus Therapeutics (PSTV)

PSTV (Cytori Therapeutics) - company brandmark

Plus Therapeutics, Inc. (PSTV) is striving for dominance in the precision isotope segment for the treatment of metastases and brain tumors. The company is implementing advanced radiopharmaceuticals based on Rhenium-186, investing in scientific research and development. The humanitarian status of the industry ensures stable operations within the US legal framework. The current value of the specific coefficient is 2.10, and the current stock quotes displayed on the GURU.Markets charts allow for an assessment of the asset's dynamics.

PSTV: plustherapeutics.com Intermediate Coverage Ratio 07/04/2022 - 08/03/2026

PSTV (Plus Therapeutics, Inc.): analytical breakdowns and indicator data

- market value and analyst target forecast:
Price Chart plustherapeutics.com|PSTV - Analyst Median Target
- company stock exchange capitalization indicators:
Market Valuation Cytori Therapeutics|PSTV - Aggregate Business Value
- book capitalization indicators:
Accounting Value per Share Plus Therapeutics|PSTV - Accounting Value of Company|Market Capitalization to Book Value Ratio plustherapeutics.com|PSTV - Cumulative Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital Plus Therapeutics, Inc.|PSTV - Long-Term Debt to Capital|Short-Term Debt to Equity plustherapeutics.com|PSTV - Company Aggregate Debt|Debts to Book Capitalization Cytori Therapeutics|PSTV - Company Long-Term Liabilities|Company Short-Term Debts Plus Therapeutics|Quick Liquidity plustherapeutics.com
- earnings and valuation multiples information:
PSTV - Final Profit
Summary company analysis:Plus Therapeutics Inc - PSTV
Flagship merchandise of plustherapeutics.com

The quick ratio measures a company's ability to settle short-term debts using its most liquid assets, completely excluding slow-moving inventories from the calculation. By analyzing operational liquidity trends, an investor can discern the real margin of safety for Plus Therapeutics, Inc. (PSTV), which is critical in the absence of revenue and amid high costs for the clinical development of radiopharmaceuticals.

Main competitors

Olema Pharma (OLMA) - Quick Liquidity|PBYI - Interim Coverage Ratio|Quick Liquidity Indicator GLSI|ZNTL (zentalis.com) - Intermediate Liquidity Ratio|Quick Liquidity Indicator MGNX (MacroGenics)|PCSA (processapharmaceuticals.com) - Intermediate Coverage Ratio|Quick Ratio EGRX (Eagle Pharmaceuticals, Inc.)